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Controversy regarding various aspects of microscopic margin
involvement (R1) in pancreatic cancer has resulted in conflicting
published data on the R1 rate and the prognostic significance of
margin involvement. In recent years, several studies indicated that
when using a standardized pathology protocol based on axial
specimen slicing and reporting margin involvement if tumour
cells are present within 1 mm from the margin, the R1 rate
increases significantly, from a traditional value around 20% to
more than 70%.1–4 However, these studies suffer from being ret-
rospective and based on a small series and/or a long study period
during which patient selection and post-operative treatment were
not uniform. In this issue of HPB, Delpero et al.5 present a mul-
ticentre study, which prospectively analysed resection margin
involvement in pancreatoduodenectomy specimens (PDEs) for
pancreatic ductal adenocarcinoma. The prospective multicentre
study design is a novelty in this area of clinical research, and the
study also distinguishes itself favourably from previous analyses
by its fairly large series (n = 150), the short study period (2 years),
and the use of a standardized pathology protocol based on axial
slicing and examination of five distinct margins [posterior, facing
the superior mesenteric vein (SMV) and artery (SMA), pancreatic
neck, and common bile duct]. Furthermore, the study is the first
to apply the quality pathology protocol to PDEs with portal vein
(PV)/SMV resection and to assess in a prospective manner the R1
rate based on a range of clearances (0–2 mm). The latter addresses
the current controversy regarding the adequate clearance on
which to base the R1 definition in pancreatic cancer.
The main observation of the study is a high R1 rate (61%–71%)
when using the standardized quality pathology protocol and
reporting margin involvement based on a clearance of < 1–2 mm.
In contrast,when applying a 0-mmclearance definition, theR1 rate
in the same PDE series is only 23%. These results confirm those of
previous studies6,7 and, given the unique methodological strength
of this study, leave little doubt that differences in the R1 rate
between previously published studies are a result of divergence in
pathology examination, not quality of surgery. This leads to the
sobering realization that a substantial number of data in the litera-
ture are difficult to interpret or compare. At the same time, the
study is encouraging because it ushers us into a new era, in which
meticulous and standardized pathology examination is a recog-
nized prerequisite for obtaining robust and reproducible data. It
highlights the responsibility, first and foremost of the profession of
pathology, to ensure that high-quality pathology examination of
pancreatic resection specimens becomes established practice.
The study by Delpero et al. makes several additional important
observations. First, the authors report that the SMV-facing
margin (SMVm) is the most frequent site of margin involvement.
What might be the reason for this? Considering the micro-
anatomy of PDEs, the finding is not surprising, because the peri-
pancreatic soft tissue layer is minimal or completely absent
between the pancreatic parenchyma and the overlying SMV-
groove, such that a ‘buffer zone’ between the infiltrating tumour
and the specimen surface is lacking. There are, however, probably
other explanations that are related to the composition of the study
series. Twenty-four percent of the PDEs included a PV/SMV
resection, indicating that nearly a fourth of the tumours had
caused significant tethering of the vein owing to infiltration
around and possibly into the vessel wall. It seems obvious that in
these cases the SMVm – and not another margin – is involved. A
similar selection bias results from the inclusion of patients, who
had undergone neoadjuvant treatment (19% of the series), mostly
for vascular engagement as the authors explain. Hence, the fact
that in 43% of the series, the tumour was located in the left-lateral
aspect of the pancreatic head and of a considerable size, such that
neoadjuvant treatment and/or PV/SMV were required, is likely to
have influenced the site of margin involvement.
The SMA-facing margin (SMAm) was found to be the second
most frequent site of R1. Considering the above and the fact that
both margins are neighbouring and of a smaller width than the
average pancreatic cancer, this finding is to be expected. However,
the authors’ conclusion that the vascular margin, i.e. the com-
bined SMVm and SMAm, is the most important, needs to be met
with caution. Both margins may be the most frequently involved,
especially in series including patients with venous resection or
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neoadjuvant treatment, but whether they are the most important
in terms of outcome remains to be seen. Results from previous
studies have been conflicting,4,8 and there is no obvious reason
why involvement of one margin should be of greater prognostic
importance than that of another, except possibly for the fact that
the density of lymphovascular channels and peripheral nerves
differs between the various areas of peripancreatic soft tissue, and
is highest in the SMA-facing region. The question of the prognos-
tic significance of the site of margin involvement may be more of
an academic interest, because if a pancreatoduodenectomy is per-
formed according to current standards, there is no scope for
extended resection at the circumferential margins. Furthermore,
as margin involvement is rarely the sole adverse factor, the site of
margin involvement – even if found to be prognostically signifi-
cant – is unlikely to influence post-operative treatment.
Heterogeneity of the case series is the main limitation of this
study. Inclusion of PDEs after neoadjuvant treatment not only
skews the distribution of the tumour site and size, it also raises
concerns over the accuracy of margin involvement, because
treatment-induced alteration of the tumour growth pattern chal-
lenges the rationale on which R1 assessment is currently based.9,10
Inclusion of invasive intraductal papillary mucinous neoplasia
with an overrepresentation of early cancers, of pT4 tumours, and
of cancers with features that are highly unusual for conventional
ductal adenocarcinoma (e.g. metastasis to 50 lymph nodes)
further compounds the issue.
As this is the first prospective multicentre study on resection
margins in pancreatic cancer, the interested reader may have ques-
tions as to how the study was conducted. How many cases were
performed in the various centres? How concurrent were the
results? Was there a dedicated study pathologist in each centre, or
were specimens reported by various staff members, including
trainees? How extensively were the resection margins sampled?
Was central pathology review undertaken and did this include
review of macroscopic pictures to ascertain the cancer origin?1,11
How were the venous resections examined, and what were the
findings regarding the depth of invasion? Although these ques-
tions pertain to critical issues in pathology quality assurance, they
are not addressed. Therefore, it is with great anticipation that we
look forward to the announced future publication of observations
from this study, because much can be expected to be learnt from
it, not only in terms of margin involvement and its clinical impli-
cations, but also regarding multicentre study design and pathol-
ogy quality control. After decades of confusion, it seems we are
now finally entering an era of controlled and systematic study.
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